Plasma concentrations of B-type natriuretic peptides (BNP) independently predict the risk of death and cardiovascular events. In the present study, we investigated the intraindividual variability of BNP concentrations, a potential confounder of risk prediction. Consecutive outpatients with blood pressure (BP) values of at least 140/90 mm Hg and not taking BP lowering therapy were asked to participate. Exclusion criteria were renal insufficiency, structural heart disease on echocardiography, except left ventricular hypertrophy and any other severe concomitant illness. Plasma BNP levels were determined on two different days using the same assay. In total, 77 patients were included. Mean age was 54712 years, 55% were male and mean systolic/diastolic BP was 163716/ 9678 mm Hg. Mean creatinine was 70714 lmol/l. The median interval between the two BNP assays was 10 days (interquartile range 1-23 days). Median BNP concentrations were 17 and 16 pg/ml for the first and second visit, respectively (P ¼ 0.48). However, there was a wide range of differences in BNP values among individual patients, 34 patients (44%) having an absolute difference of at least 10 pg/ml. When patients were categorized according to tertiles of BNP levels, 25 (32%) changed from one tertile at the first visit to another at the second visit. In conclusion, these data indicate that BNP levels may be used on a population level. However, the high intraindividual variability seems to preclude useful risk stratification in the individual patient. Care should be taken in the interpretation of single BNP values below the currently accepted thresholds for heart failure.
Introduction
Recently, data from the Framingham study showed that increasing concentrations of B-type natriuretic peptides (BNP) independently predict the occurrence of death and cardiovascular events in the general population.
1 B-type natriuretic peptides levels predicting cardiovascular events in this cohort were well below contemporary thresholds used for the diagnosis of heart failure (80-100 pg/ ml). However, to correctly interpret single BNP measurements in individual patients, other parameters have to be taken into account. Besides renal dysfunction, 2 body mass index 3 or age, 4 a high intraindividual variability of BNP concentrations may substantially hamper the interpretation of results. Information about variability is also important for the correct interpretation of serial test results, for example, when BNP-guided therapy in patients with congestive heart failure is considered. 5 Several small studies analysed the variability of BNP concentrations either in healthy individuals 6 or in patients with stable congestive heart failure. [7] [8] [9] These studies found a high coefficient of variation for BNP measurements at different points in time. To our knowledge, no study analysed intraindividual BNP variability in daily practice. As blood pressure (BP) lowering therapy influences BNP concentrations, 10,11 data from patients not receiving such therapy are needed. Finally, BNP variability on a group or population level has not been assessed.
Therefore, the aim of the present study was to assess prospectively the intraindividual variability of BNP concentrations in patients with untreated hypertension. A second aim was to analyse the stability of median BNP concentrations on a group level.
Methods

Study population
The study population consisted of consecutive patients with untreated hypertension, who attended the Medical Outpatient Department. Patients were included into the study if the average of two BP readings on the initial screening visit was X140 mm Hg for systolic BP and/or X90 mm Hg for diastolic BP. Patients receiving nonsteroidal antiinflammatory drugs, immunosuppressive or any BP lowering therapy were not considered. Further exclusion criteria were heart failure, infection, renal insufficiency (creatinine 4133 mmol/l (1.5 mg/dl)), atrial fibrillation or any other severe concomitant illness. Blood pressure was measured twice with a standard mercury sphygmomanometer in a quiet environment and in a sitting position after at least 5 min of rest. At the first visit, clinical history, physical examination and routine laboratory profile including BNP were obtained. At the second visit, standard 12-lead electrocardiography, echocardiography and 24 h BP monitoring (using a validated device; Mobilograph, Stolberg, Germany) were performed and another blood sample to measure BNP concentrations was taken. The study complies with the Declaration of Helsinki, and it was approved by the local ethics committee. Written informed consent was obtained from all subjects.
Laboratory analysis
Non-fasting venous blood samples were collected in ethylene diamine tetraacetic acid (EDTA) containing tubes and processed immediately. All blood samples were taken in the morning hours to avoid BNP changes during the day. 7 Plasma BNP concentrations were determined by immunofluorescence (AxSYM s , Abbott laboratories). The intra-assay variation was 5.2-5.5%. 12 The lower detection limit of the assay was 10 pg/ml. Concentrations for BNP below the detection limit were assigned a value of 5 pg/ml.
Statistical analysis
Continuous variables are expressed as mean7s.d. or median (interquartile range (IQR)). Qualitative parameters are given as proportions (percentage). Between-group differences were compared using the Mann-Whitney test or Wilcoxon test. Spearman's correlation coefficient was calculated for BNP concentrations at different visits. Individual between-visit differences in BNP concentrations were plotted against mean individual BNP concentrations (Bland-Altman plot). 13 A two-tailed P-value of less than 0.05 was considered to indicate statistical significance. Statistical analysis was performed with SPSS software package, version 12.0 (SPSS Inc., Chicago, IL, USA).
Results
Between October 2003 and August 2004, 77 consecutive patients fulfilling the inclusion criteria and willing to participate were analysed. Baseline characteristics are given in Table 1 . All patients had previously unknown hypertension and none had documented arteriosclerotic disease. The median interval between the two visits was 10 days (IQR 1-23 days). Overall, there were no significant differences of BNP concentrations between the visits (median BNP concentrations 17 pg/ml (IQR 7-34 pg/ ml) versus 16 pg/ml (IQR 8-36 pg/ml), P ¼ NS) (Figure 1 ). There were no significant differences in baseline characteristics and BNP concentrations between patients with a visit interval below the median compared to those with an interval above the median (data not shown). The median difference was 3 pg/ml for patients with an interval below the median of 10 days and 2 pg/ml for those with an interval of more than 10 days between visits (P ¼ NS). The Spearman correlation coefficient for BNP concentrations at different visits was 0.77 (Po0.001). However, there were substantial intraindividual differences in BNP concentrations between the two visits ( Figure 2) . Thirty-four patients (44%) had a difference of at least 10 pg/ml. When patients were categorized into tertiles according to BNP concentrations, 25 (32%) changed from one tertile at the first visit to another at the second visit (Table 2) . A Bland-Altman plot revealed that between visit differences tended to be higher in patients with higher mean BNP concentrations ( Figure 3 ).
Discussion
Our results indicate that individual BNP concentrations vary considerably. In our population, 44% of patients had a difference in BNP concentrations of at least 10 pg/ml. Considering the low median BNP 1 However, we found that median BNP concentrations in the whole patient group were stable. These findings suggest that BNP could be used for risk stratification or treatment monitoring on a group or population basis. For example, median BNP levels may be used as a surrogate marker in the analysis of a specific intervention in patients with heart failure.
Several studies tried to identify patients with asymptomatic left ventricular dysfunction or left ventricular hypertrophy using a single BNP measurement. 14, 15 Sensitivity and specificity of various cutoff levels were suboptimal in most studies. Our findings of a large individual, day-to-day variability could at least partly explain why BNP alone is not useful for the diagnosis of impaired left ventricular function. Whether two individual BNP measurements improve the diagnostic yield has not been assessed. Despite this variability, the usefulness of BNP has been shown in patients with acute dyspnoea in the emergency department. 16, 17 The Finally, this study further confirms that hypertensive patients have higher BNP levels than those reported in patients without hypertension. 18, 19 Thus, even in young low-risk patients with normal renal function, a very low prevalence of left ventricular hypertrophy and without known arteriosclerosis, median BNP concentrations are approximately twice the levels observed in the general population. 1 A limitation of this study is that only hypertensive patients were analysed. We chose this population because risk stratification is an essential part in the management of these patients. 20 Furthermore, these results confirm the variability of BNP in patients not taking BP lowering drugs, which are known to influence BNP levels. 10, 11 Then, variability of NTpro-BNP was not examined. However, previous studies found no difference in analytical variation between BNP and NT-pro-BNP in patients with heart failure. 7 In conclusion, median BNP concentrations in a population of untreated hypertensives are stable over time and may be used for risk prediction or monitoring of interventions. However, the high intraindividual of BNP concentrations seems to preclude its usefulness for individual risk stratification or treatment guidance. Therefore, care should be taken in the interpretation of single BNP values below the currently accepted thresholds for heart failure.
